Very Early Prevention of Stroke Recurrence

Cerebrovascular Diseases

Volumn 7, Issue , 1997, Pages 10-15

  Sandercock, P ^a   Tangkanakul, C ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Recurrent stroke; Stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANGIOPLASTY; CONFERENCE PAPER; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE;

EID: 0031027911     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108231     Document Type: Article

References (31)

1. Hart RG, Coull BM, Hart D: Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective studv. Stroke 1983: 14:688-693.
2. Sage JI, Van Uitert RL: Risk of rccurrenl stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke 1983; 14: 537-540.
3. Furlan AJ, Cavalier SJ, Hobbs RE, Weinstein MA, Modic MT: Hemorrhage and anticoagula-lion after nonseptic embolic brain infarction. Neurology 1982:32:280-282.
4. Sackett DL, Haynes RB, Guvatt GH, Tugwell P (eds): Clinical Epidemiology: a basic science for clinical medicine. Little. Brown and Company 1991. pp 173-185.
5. Bamford J, Sandercock P, Dennis M, Bum J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991:337:1521-1526.
6. Counsell C, Warlow C, Sandercock P. Fraser H, Van Gijn J: The Cochrane Collaboration Stroke Review Group. Meeting the need for systematic reviews in stroke care. Stroke 1995: 26:498-502.
7. Counscll C, Sandercock P: Efficacy and safety of anticoagulant therapy in patients with acute presumed ischaemic stroke: a systematic review of the randomised trials comparing anticoagulants with control; in Warlow C. Van Gijn J. Sandercock P (eds): Stroke Module of Cochrane Database of Systematic Reviews (updated 01 September 1996). Available in The Cochrane Library (database on disk and CDROM). The Cochrane Collaboration: Issue 3, Oxford: Update Software: 1996. Updated quarterly. Available from BMJ Publishing Group. London.
8. Counscll C, Sandercock P: Efficacy and safety of antiplatelet therapy in patients with acute presumed ischaemic stroke: A systematic review of the randomised trials comparing immediate antiplatelet therapy with control: in Warlow C, Van Gijn J, Sandercock P (eds): Stroke Module of Cochrane Database of Systematic Reviews (updated 01 September 1996). Available in The Cochrane Library (database on disk and CDROM). Tile Cochrane Collaboration; Issue 3, Oxford: Update Software; 1996. Updated quarterly. Available from BMJ Publishing Group, London.
9. Bogousslavskv J, Mellc GV, Regli F: The Lausanne Stroke Registry: Analysis of 1000 consecutive patients with first stroke. Stroke 1988:19: 1083-1092.
10. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hicr DB, Price TR: Determinants of early recurrence of cerebral infarction: the Stroke Data Bank. Stroke 1989:20:983-989.
11. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM: Duration of atrial fibrillation and imminence of stroke. The Framingham Study. Stroke 1983:14:664-667.
12. Lauria G, Gentile M, Fassetta G, Casetta I, et al: Incidence and prognosis of stroke in the Bel-luno Province. Italy: First year results of a community-based study. Stroke 1995:26:1787 - 1793.
13. Sacco RL, Shi T, Zamanillo MC, Kargman DE: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The North Manhattan Stroke Study. Neurology 1994:44:626-634.
14. Ricci S, Celani MG. Duca E, Scaroni R. et al: Ischaemic stroke and atrial fibrillation: A community based, case-control study. Cercb Vase Dis 1991:8:7-11.
15. Gustafsson C, Britton M: Pathogenetic mechanism of stroke in NVAF: Follow up of stroke patients with and without AF. J Intern Med 1991:230:11-16.
16. D'Alcssandro G, Marco DG, Roveyaz L. Ian-nizzi L, et al: Incidence and prognosis of stroke in the Valle d'Aosta, Italy: First-year results of a community-based study. Stroke 1992:23: 1712-1715.
17. Boiten J. Lodder J: Prognosis for survival, handicap and recurrence of stroke in lacunar and superficial infarction. Cerebrovasc Dis 1993;3: 221-226.
18. Samuelsson M, Lindell D, Norrving Bo: Presumed pathogenetic mechanisms of recurrent stroke after lacunar infarction. Cerebrovasc Dis 1996;6:128-136.
19. Broderick JP, Phillips SJ, O'Fallon M, Frye R, Whisnant JP: Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992;23:1250-1256.
20. Fisher CM: Reducing risks of cerebral embolism. Geriatrics 1979;34:59-66.
21. Roller RL; Recurrent embolic cerebral infarction and anticoagulation. Neurology (NY) 1982;32:283-285.
22. International Stroke Trial Pilot Study Collaborative Group: Study design of the International Stroke Trial (1ST), baseline data, and outcome in 984 randomised patients in the pilot study. J Neurol Neurosurg Psychiatry 1996:60:371-376.
23. Marsh EE, Adams HP, Biller J, Wasck P, Ban-wart K, Mitchell V, Woolson R: Use of antithrombotic drugs in the treatment of acute ischaemic stroke. A survey of neurologists in practice in the United States. Neurologv 1989: 39:1631-1634.
24. Lindlcy RI, Amavo EO, Marrshall J, Sandercock PAG, Dennis M, Warlow CP: Acute stroke treatment in UK hospitals: the Stroke Association survey of consultant opinion. J R Coll Physicians Lond 1995:29:479-484.
25. Hakim AM, Furlan AJ, Hart RG: Immediate anticoagulation of embolic stroke: a randomised trial. The Cerebral Embolism Study Group. Stroke 1983:1-1:668-676.
26. Sandercock P, van den Belt ACM, Lindley RI, Slattery J: Antithrombotic therapy in acute ischacmic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993:56:17-25.
27. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of anti-platelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
28. European Carotid Surge O' Trialists' Collaborative Group: MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235-1243.
29. North American Symptomatic Carotid Endar-tercctomv Trial Collaborators: Beneficial effect of carotid endartereclomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-465.
30. Rothwell PM, Slattery J, Warlow CP: A systematic comparison of the risks of stroke and death due to carotid endartereclomy for symptomatic and asymptomatic stenosis. Stroke 1996:27:266-269.
31. Major Ongoing StrokeTrials. Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS). Stroke 1996:27:358